Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast. Read more about Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast.
A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. Read more about A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel.
Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol. Read more about Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. Read more about Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. Read more about 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer.
Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer. Read more about Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer.
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. Read more about Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis. Read more about Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis.
Erratum: Author Correction: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. Read more about Erratum: Author Correction: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.
The WISDOM Study: breaking the deadlock in the breast cancer screening debate. Read more about The WISDOM Study: breaking the deadlock in the breast cancer screening debate.
